All Episodes
GRACEcast - Discussions with the Global Resource for Advancing Cancer Education — 249 episodes
Qualifying for Clinical Trials, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #5
Communication and Catharsis, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #4
Family, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #3
Liminal Space, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #2
My Cancer Journey, LuAnne Sirdiak, GRACE Clinical Trials Storytelling 2026 #1
Treatment Options for Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Symptoms of Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Diagnostic Lab Tests in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Genetic Testing in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Understanding NCCN Guidelines in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Risk Factors for Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Epidemiology of Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Pancreatic Cancer Anatomy- Gastrointestinal Cancers OncInsights 2025-26
Staging and Prognosis in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Diagnostic Imaging in Pancreatic Cancer- Gastrointestinal Cancers OncInsights 2025-26
Advanced Basal Cell Carcinoma
Management of High-Risk Basal Cell Carcinoma
Management of Low-Risk Basal Cell Carcinoma
Skin Cancer Treatment for Non-Surgical Candidates
Basal Cell Carcinoma- Risk Factors and Diagnosis
Systemic Therapy for Skin Cancer
Should I Have Mohs Surgery?
Melanoma: Warning Signs and Risk Management
Follow Up and Prevention for Basal Cell Carcinoma
Utilizing Mohs Surgery for Skin Cancer Treatment
Basal and Squamous Cell Carcinoma: An Overview
Skin Cancer Facts and Figures
Trials in EGFR Mutated NSCLC: Flaura2 and Mariposa- 2024 Leading Developments in Lung Cancer
Trials in ALK+ NSCLC: The Crown Study- 2024 Leading Developments in Lung Cancer
Limited Stage Small Cell Lung Cancer: The Adriatic Study- 2024 Leading Developments in Lung Cancer
Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung Cancer
Tarlatamab for Extensive Stage Small Cell Lung Cancer- 2024 Leading Developments in Lung Cancer
Staging Skin Cancer
Advances in Thyroid Cancer Treatment
Incurable HPV Negative Head and Neck Cancer
Recurrent/Metastatic HPV Positive Head and Neck Cancer
Curable HPV Negative Head and Neck Cancer
Curable HPV Positive Head and Neck Cancer
What is a Bone Marrow Transplant?
Q&A: Do People in Rural Communities Have Equal Access to Treatment Options?
Q&A: Is my Clinical Trial Affecting my Body's Reaction to the Covid-19 Vaccine?
Bispecific Antibodies in Myeloma: Approvals and Clinical Trials
Curative Strategies for Patients with Smoldering Multiple Myeloma
Management of Bispecific Antibodies Side Effects
Teclistamab, Talquetamab, and Elranatamab: Response Rates and Data
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
Barriers to Biomarker Testing: Cost and Insurance
Barriers to Biomarker Testing: Ordering Tests
The Adaura Trial: The Effect on EGFR+ Treatment
Biomarker Driven Therapy for NSCLC
Current Recommendations and Best Practices for Biomarker Testing
The Importance of Biomarker Testing: What is Liquid Biopsy?
Biomarkers in NSCLC
Key Points from the Adaura Trial: Osimertinib
Biomarkers in NSCLC
The Importance of Biomarker Testing: What is Liquid Biopsy?
Barriers to Biomarker Testing: Cost and Insurance
Neoadjuvant Treatment for Patients with NSCLC
The Alina Trial for ALK+ NSCLC
Local Therapy for Limited Metastatic NSCLC
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
Local Therapy for NSCLC Patients After Frontline Therapy
The Role of the Patient as Advocate
Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
Local Therapy for Patients with Oligoprogressive NSCLC
The Future of Local Therapy in Lung Cancer
Adding to Targeted Therapy: Current Statistics and Biology
The Importance of Prostate Cancer Screening
सामान्य परामर्श मुद्दे (Common Consultation Issues)
पुरुषत्वीकरण चिकित्सा और द्वितीय एरिथ्रोसाइटोसिस (Masculinizing Therapy and Secondary Erythrocytosis)
सिकल सेल रोग और जेंडर अफर्मिंग हार्मोन थेरेपी (Sickle Cell Disease and Gender Affirming Hormone Therapy)
फेमिनाइजिंग थेरेपी और थ्रोम्बोसिस (Feminizing Therapy and Thrombosis)
भारत में ट्रांसजेंडर मुद्दे (Transgender Issues in India)
Neoadjuvant Therapy in Melanoma: Does It Give a Better Immune Response?
Neoadjuvant Therapy for Melanoma
Adjuvant Therapy for Melanoma
Adjuvant Therapy in Stage 3 and 4 Melanoma
Patient Selection for First Line Therapy in Stage 4 Melanoma
Neoadjuvant Therapy in Melanoma: The PRADO Trial
Major Advances in Uveal Melanoma
Clinical Trials in Melanoma
Incidence Trends in Melanoma
Side Effects of Immunotherapy in Melanoma
Treatment for Metastatic Melanoma
BRAF Mutated Melanoma
Melanoma and Current Treatment Options
Emerging Types of CAR T-Cell Therapy
CAR T-Cell Therapy Side Effects
CAR T-Cell Therapy for Patients with Relapsed Diffuse Large B-Cell Lymphoma
Treatment Options for Relapsed Diffuse Large B-Cell Lymphoma
Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: Bispecific Antibodies
Emerging Immunotherapy Treatments for B-Cell Non-Hodgkin's Lymphoma: CAR-T Cells
Covid-19 and Lung Cancer Screening
Who Should Receive Lung Cancer Screening?
What is Involved in Lung Cancer Screening?
Timelines in Cancer Care
Efficiency and Effectiveness of Cancer Care
Is My Lung Cancer Mutation Genetic?
The Prevalence of Breast Cancer and Tools for Early Detection
Types of Imaging Tests for Breast Cancer
Anomalies on Breast Cancer Imaging: Next Steps
The Importance of Patient Centered Care
Symptoms of Breast Cancer
Key Players for Lung Cancer Program Success
Treatment After Diagnosis of Breast Cancer
Goals of Lung Cancer Advocacy
The Importance of Breast Cancer Screening
Prevalence of EGFR-Mutant NSCLC in Asian and Caucasian Communities
Advancements of Targeted Therapy for EGFR Mutations in NSCLC
Choosing First Line Therapy in EGFR Mutations
Osimertinib and the FLAURA Trial
Preferential Timing for Molecular Testing in NSCLC
Immunotherapy Before Surgery in NSCLC
Immunotherapy for Patients with Driver Mutation
Immunotherapy for Oligometastatic Disease
Gene Mutations in NSCLC
Testing Methodology for NSCLC: Immunohistochemistry
Testing Methodology for NSCLC: FISH
Testing Methodology for NSCLC: PCR Testing
Testing Methodology for NSCLC: Next Generation Sequencing (NGS)
Circulating Tumor DNA in NSCLC
Mesothelioma Updates, Episode 6: Peritoneal Disease
Mesothelioma Updates, Episode 5: Future Approaches
Mesothelioma Updates, Episode 4: Chemo and Immunotherapy
Mesothelioma Updates, Episode 3: Surgical Options
Mesothelioma Updates, Episode 2: Diagnosis and Staging
Mesothelioma Updates, Episode 1: Epidemiology
Targeted Therapy Forum, Episode 10: Cost and Treatment Options
Targeted Therapies Forum, Episode 9: Telemedicine and Cancer
Targeted Therapies Forum, Episode 8: Detecting TKI Resistance with Liquid Biopsy
Targeted Therapies Forum, Episode 7: Pleural Fluid or Blood Biopsy?
Targeted Therapies Forum, Episode 6: Coverage, Cost, and Standard of Care for Biopsy
Targeted Therapies Forum, Episode 5: Circulating Tumor DNA
Targeted Therapies Forum, Episode 4: Diagnosis and Testing Relevance
Targeted Therapies Forum, Episode 2: The Complimentary Use of Liquid and Tissue Biopsies
Targeted Therapies, Episode 3: Anxiety and Symptom Burden
Targeted Therapies Forum 2021, Episode 1: Liquid and Tissue Biopsies in Acquired Resistance
Melanoma Updates - Molecular Profiling and Driver Mutations in Melanoma Treatment
Melanoma Updates - The Importance of Screening for Skin Cancers
Melanoma Updates -- Leptomeningeal Disease/ Brain Mets in Melanoma
Melanoma Updates The Role of Neoadjuvant Treatment in Melanoma Care
Melanoma Updates Treatment Options for Metastatic Melanoma
Melanoma Updates Potential Toxicities Associated with Immunotherapy in the Treatment of Melanoma
Brain Metastases in Breast Cancer Treatment Options and Efficacy
Brain Metastases in Breast Cancer Risks of Developing Brain Metastasis in Breast Cancer
Telemedicine vs. In-Person Treatment: What Have we Learned?
Is There a Place for Telemedicine in Oncology?
Opening Up and Masking: Is it Safe?
The Oncologist's Role: Educating Patients During a Pandemic
The Variable Acceptance of the Covid Vaccine
Brain Metastases in Breast Cancer Treatment Options for Breast Cancer Patients who Relapse with Only CNS Metastases
Brain Metastases in Breast Cancer, Prognosis and Impact on Survival
Melanoma Updates - Adjuvant Treatment Options for Melanoma
Metastatic Triple Negative Breast Cancer Immunotherapy Treatment Options and Potential Side Effects
Recent Data and Developments in Palliative Head and Neck Cancer Treatments
Palliative Care and Studies for Incurable Head and Neck Cancers
HPV and Head and Neck Cancers
Curative Modalities and Immunotherapy for Head and Neck Cancers
Metastatic Triple Negative Breast Cancer Antibody-Drug Conjugate Treatment Options
Metastatic Triple Negative Breast Cancer Targeted Therapy Treatment Options and Potential Side Effects
Surgical Management in Breast Cancer Body Image and Reconstruction Surgery
Surgical Management in Breast Cancer What to Expect During Surgery
Surgical Management in Breast Cancer Long Term Outcomes - Breast Conserving Therapy vs. Mastectomy
Surgical Management in Breast Cancer What to Expect After Surgery
Surgical Management in Breast Cancer The Role of Different Types of Surgery and the Management of Patients with Breast Cancer
Surgical Management in Breast Cancer Prophylactic Mastectomy on the Opposite Breast
Brain Metastases in Breast Cancer Signs, Symptoms, Screening and Treatment for Brain Metastases in Breast Cancer
Surgical Management in Breast Cancer Surgical Removal of Lymph Nodes - Sentinel Lymph Node Biopsy vs. Axillary Lymph Node Dissection (ALND)
GraceCAST 2021 Spanish COVID Panel-Vacunas contra el COVID en pacientes con cancer
GraceCAST 2021 Spanish COVID Panel- Usos de la Telemedicina para pacientes con cancer
GraceCAST Spanish COVID Panel-Impacto de la Covid-19 en la atención de pacientes con cáncer
GraceCAST Podcast-2021 English Q1 COVID Panel- COVID-19 Variants and the Challenge for Cancer Care
GraceCAST Podcast-2021 English Q1 COVID Panel- What Patients Should Expect Post COVID-19 Vaccination
GraceCAST Podcast-2021 English Q1 COVID Panel- The Continued Use of Telemedicine in Cancer Treatment
GraceCAST Podcast-2021 English Q1 COVID Panel- Is the COVID-19 Vaccine Safe For Cancer Patients
GraceCAST 2021 COVID Panel - Changes and Challenges of Consistent Cancer Care During the Pandemic
GraceCAST 2021 COVID Panel - COVID 19 Pandemic and the Impact on Cancer Care
GRACECast - Are there alternatives to radiation for patients with brain metastases
GRACECast - What is the optimal treatment for patients with advanced NSCLC and a BRAF-V600E mutation
GRACECast - What is tumor mutational burden TMB and could it be helpful in lung cancer management today
GRACECast - Treatment Options for Metastatic NSCLC
GRACEcast - Are there treatment options for patients with HER-2 NSCLC
PODCAST-GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- KRAS
GRACEcast- Dr. Sandip Patel- Emerging Molecular Targets in NSCLC- EGFR Exon 20
GRACEcast- ASCO LUNG 2020- Enhertu and the Potential for Treatment of HER2 Positive NSCLC
GRACEcast- ASCO LUNG 2020- The SINDAS Trial - The Addition of SBRT to a Systemic EGFR inhibitor TKI in EGFR positive NSCLC
GRACEcast- ASCO LUNG 2020- New Potential Treatments for MET and RET Positive NSCLC Capmatinib-Tabrecta and BLU-667-Pralsetinib
GRACECast - LCVL Can EGFR inhibitor therapy treat and prevent brain metastases
GRACECast - LCVL- What are the options after a patient with an ALK-positive advanced NSCLC develops resistance on Alecensa-alectinib
GRACECast - LCVL - Can immunotherapy help frail patients with advanced NSCLC
GRACECast - LCVL What is the role of immunotherapy for unresectable Stage 3 NSCLC today
GRACECast - LCVL - H. Jack West MD - Can ALK inhibitors treat and prevent brain metastases
GRACECast - LCVL - Can blood-based mutation-testing help shape treatment decisions for advanced NSCLC
GRACECast - LCVL - Consolidation immunotherapy after chemo-radiation for stage 3 unresectable NSCLC
GRACECast - LCVL -Can local therapies improve outcomes for stage IV NSCLC?
GRACECast - LCVL - Could pre-operative immunotherapy improve outcomes in early stage NSCLC
GRACECast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced nonsquamous NSCLC today
GRACECast - LCVL - Can patients with an EGFR mutation-positive advanced NSCLC benefit from immunotherapy
GRACEcast - LCVL - What are the leading first line treatment options for advanced NSCLC harboring an ALK rearrangement today
GRACEcast - LCVL - Can immunotherapy help patients with small cell lung cancer
GRACEcast - LCVL - Leading treatment options for patients with low or negative tumor PD-L1 expression and advanced squamous NSCLC today
GRACEcast - LCVL - What is the best first line treatment for patients with advanced EGFR mutation-positive NSCLC today
GRACEcast - LCVL - Which patients with advanced NSCLC are good candidates for first line immunotherapy alone today
GRACEcast - LCVL What is the current standard of care for patients with extensive stage small cell lung cancer
GRACEcast - Treatment options for patients with NSCLC and high tumor PD-L1 expression
GRACEcast - Treatment options for patients with advanced NSCLC and a HER2- ERBB2 mutation
GRACECast - Does immunotherapy have activity in malignant pleural mesothelioma
GRACEcast - Leading Treatment Options for Patients with Negative Tumor PD-L1 NSCLC with Dr. Stephen Liu
GRACEcast - Immunotherapy for Small Cell Lung Cancer with Dr. Stephen Liu
GRACEcast - Emerging Molecular Targets in NSCLC- RET Fusions with Dr. Josh Bauml
GRACEcast - Emerging Molecular Targets in NSCLC- MET with Dr. Josh Bauml
GRACEcast 2020 - Updates in Small Cell Lung Cancer with Dr. Jared Weiss
GRACEcast 2020 - New TKIs for Stage IV Non Small Cell Lung Cancer Mutations with Dr. Jared Weiss
GRACEcast 2020- Treatment Option Explored in the ADAURA Trial with Dr. Jared Weiss
Case Based Panel Discussion - EGFR Mutation Patient Progression and Next Steps
Case Based Panel Discussion - EGFR Mutation and High PDL1 - What is the Role of Immunotherapy in Treatment Decisions
Case Based Panel Discussion - EGFR Mutation with MET Amplification Treatment Decisions and the Importance of the Level of MET Amplification
Webside Discussions Update - Pt 3 - Challenges and the Future for In Person Patient Care
Webside Discussions Update Pt 2 - Update on the Use of Telemedicine in Patient Care During the Pandemic
Webside Discussion Update Part 1- How Has the Coronavirus Pandemic Changed Cancer Management in Patient Care
Case Based Panel Discussion - What is the Recommended Treatment for Common EGFR Mutations
Case Based Panel Discussion - EGFR Mutation Treated with Tagrisso Progression While on Treatment, and What is the Role of Repeat Biopsy
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 3
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 2
Webside Manner - Remote Delivery of Medical Info and Care, Rapid Expansion of Telemedicine - Part 1
Case Based Panel Discussion - EGFR Mutation Oligoprogression in Brain and or Body vs Worsening Progression What are the Treatment Options?
Case Based Panel Discussion 3.1 EGFR Mutation - Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?
Case Based Panel Discussion 2.2 Patient with Asymptomatic Brain Metastases -Focal Radiation Before Alk Inhibitor or Begin with ALK Inhibitor
Case Based Panel Discussion 2.1 Patient with Good Performance Status, Lung Adenocarcinoma, Metastatic Disease Adrenal Lesion
Case Based Panel Discussion 2.4 Initial Brain Mets Progression in Body After Success on ALK Inhibitor
Case Based Panel Discussion 2.5 Progression After ALK Inhibitors Is There a Role for Combination Therapies
Case Based Panel Discussion 2.3 Developing Resistance to Alk Inhibitors, Areas of Progression After Years of Success Treatment Approach
Case Based Panel Discussion 2.7 Clinical Significance of HER2 Mutation How Does a Positive HER2 Mutation Effect Treatment Decisions in NSCLC
Case Based Panel Discussion 2.6 ALK Positive and High PDL1 First Line Treatment for Potentially Competing Targets
Case Based Panel Discussion 2019 3. EGFR Uncommon Exon 20 Mutation - Suggested Treatments Targeted Therapy and Clinica Trial
Corona Virus and Covid 19 - Key Questions Part Four - Is the Standard Care Changing for Cancer Patients Because of the Pandemic?
Corona Virus and Covid 19 - Key Questions Part Three - What Preventive Measures are Trustworthy?
Corona Virus and Covid 19 - Key Questions Part Two - Do Cancer Patients Have a Higher Risk?
Corona Virus and Covid 19 - Key Questions Part One - Should Cancer Patients Get Tested?
Case Based Panel Discussion 2019 3.2 EGFR Mutation and the FLAURA Trial, Is There a Difference in Data Based on Demographics
Unresectable NSCLC - Does Checkmate 227's Suggestion of an Immunotherapy Combination of Yervoy and Opdivio Offer Another Treatment Option?
Unresectable NSCLC - Tumor Mutational Burden (TMB), the Value in Testing
Unresctable NSCLC - Concurrent Chemo & Radiation, Followed By Immunotherapy, Potential Pneumonitis Following Durvalumab (Imfinzi)
Unresectable NSCLC - For Varying Patient Scenarios, Fragile Patient, Attrition after 8-9 Months, What is the Best Schedule for Durvalumab
Unresectable NSCLC - Treatment Standard Concurrent Chemo & Rad Followed by Immunotherapy, Approach for Patients with PDL1 Score of 0
Unresectable NSCLC - Does Timing of Treatment Make a Difference in Response
Unresectable NSCLC In a Frail Patient with Competing Risks Is the Standard Treatment the Best Approach
Unresectable NSCLC - Should Molecular Tests Be Considered and Would Outcome Effect Treatment Decisions